It is well accepted that tumor-specific CD4+ T cells essentially sustain the anti-tumor activity of CTL by licensing dendritic cells (DC) to effectively prime CTL [17], [18] or by maintaining profound CTL memory [19], as well as by direct stimulation of CTL [20]. Here, CD4 is linked to neoplasm.